CALCIGENIX Trademark

Trademark Overview

On Monday, March 4, 2013, a trademark application was filed for CALCIGENIX with the United States Patent and Trademark Office. The USPTO has given the CALCIGENIX trademark a serial number of 85865449. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 24, 2016. This trademark is owned by CalciGenix, LLC. The CALCIGENIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of neurodegenerative diseases and calcium dyshomeostasis
calcigenix

General Information

Serial Number85865449
Word MarkCALCIGENIX
Filing DateMonday, March 4, 2013
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 24, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 23, 2013

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of neurodegenerative diseases and calcium dyshomeostasis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 8, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCALCIGENIX, LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressHEATH, TX 75032
Party NameCalciGenix, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressHeath, TX 75032
Party NameCalciGenix, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHeath, TX 75032

Trademark Events

Event DateEvent Description
Monday, October 24, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 24, 2016ABANDONMENT - NO USE STATEMENT FILED
Saturday, March 19, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 18, 2016EXTENSION 5 GRANTED
Thursday, March 17, 2016EXTENSION 5 FILED
Thursday, March 17, 2016TEAS EXTENSION RECEIVED
Tuesday, September 22, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 21, 2015EXTENSION 4 GRANTED
Tuesday, September 15, 2015EXTENSION 4 FILED
Tuesday, September 15, 2015TEAS EXTENSION RECEIVED
Thursday, March 26, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 25, 2015EXTENSION 3 GRANTED
Tuesday, March 17, 2015EXTENSION 3 FILED
Tuesday, March 17, 2015TEAS EXTENSION RECEIVED
Friday, September 26, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 25, 2014EXTENSION 2 GRANTED
Tuesday, September 16, 2014EXTENSION 2 FILED
Thursday, September 25, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 16, 2014TEAS EXTENSION RECEIVED
Wednesday, March 12, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 10, 2014EXTENSION 1 GRANTED
Monday, March 10, 2014EXTENSION 1 FILED
Monday, March 10, 2014TEAS EXTENSION RECEIVED
Tuesday, September 17, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 23, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2013PUBLISHED FOR OPPOSITION
Wednesday, July 3, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, June 15, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, June 15, 2013ASSIGNED TO EXAMINER
Wednesday, May 1, 2013ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Friday, March 8, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, March 7, 2013NEW APPLICATION ENTERED IN TRAM

Related Keywords

calcigenix diseases calcium dyshomeostasis neurodegenerative prevention preparations treatment pharmaceutical